Resistance of Targeted Therapies Excluding Antibodies for Lymphomas
In the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these thera...
Uloženo v:
| Médium: | Elektronický zdroj E-kniha |
|---|---|
| Jazyk: | angličtina |
| Vydáno: |
Cham :
Springer International Publishing,
2018.
|
| Vydání: | 1st ed. 2018. |
| Edice: | Resistance to Targeted Anti-Cancer Therapeutics,
17 |
| Témata: | |
| ISBN: | 9783319751849 |
| ISSN: | 2196-5501 ; |
| On-line přístup: |
|
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 003 | SK-BrCVT | ||
| 005 | 20220618101652.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 180404s2018 gw | s |||| 0|eng d | ||
| 020 | |a 9783319751849 | ||
| 024 | 7 | |a 10.1007/978-3-319-75184-9 |2 doi | |
| 035 | |a CVTIDW13619 | ||
| 040 | |a Springer-Nature |b eng |c CVTISR |e AACR2 | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Resistance of Targeted Therapies Excluding Antibodies for Lymphomas |h [electronic resource] / |c edited by Andrés J. M. Ferreri. |
| 250 | |a 1st ed. 2018. | ||
| 260 | 1 | |a Cham : |b Springer International Publishing, |c 2018. | |
| 300 | |a XIII, 138 p. 14 illus., 13 illus. in color. |b online resource. | ||
| 490 | 1 | |a Resistance to Targeted Anti-Cancer Therapeutics, |x 2196-5501 ; |v 17 | |
| 500 | |a Biomedical and Life Sciences | ||
| 505 | 0 | |a Chapter 1 BTK inhibitors: focus on ibrutinib and similar agents -- Chapter 2 BCL2 Inhibitors: insights into resistance -- Chapter 3 Proteasome Inhibitors with a Focus on Bortezomib -- Chapter 4 IMiD - immunomodulatory drug lenalidomide (CC-5013; Revlimid) in the treatment of lymphoma: Insights into clinical use and molecular mechanisms -- Chapter 5 mTOR inhibitors, with special focus on temsirolimus and similar agents -- Chapter 6 Inhibitors of the JAK/STAT pathway, with a focus on ruxolitinib and similar agents. | |
| 516 | |a text file PDF | ||
| 520 | |a In the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these therapies, with special emphasis on molecular mechanisms and clinical effects of resistance. The knowledge of the underlying mechanisms involved in tumor resistance to target therapies is of paramount importance because they will result in a better selection of patients with sensitive disease and the establishment of suitable combinations of drugs that target different molecules and could overcome the established resistance. . | ||
| 650 | 0 | |a Cancer research. | |
| 650 | 0 | |a Molecular biology. | |
| 856 | 4 | 0 | |u http://hanproxy.cvtisr.sk/han/cvti-ebook-springer-eisbn-978-3-319-75184-9 |y Vzdialený prístup pre registrovaných používateľov |
| 910 | |b ZE10899 | ||
| 919 | |a 978-3-319-75184-9 | ||
| 974 | |a andrea.lebedova |f Elektronické zdroje | ||
| 992 | |a SUD | ||
| 999 | |c 238055 |d 238055 | ||